Other languages Johnson & Johnson

Equities

JNJ

US4781601046

Market Closed - Nyse Other stock markets 04:00:02 2024-06-10 pm EDT			5-day change	1st Jan Change
147.1 ^USD	+0.03%		-0.41%	-6.13%

Jun. 08	Top law firms in US opioid lawsuits to get hundreds of millions in fees	RE
Jun. 07	J&J-backed Rapport Therapeutics shares debut nearly 6% higher	RE

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Top law firms in US opioid lawsuits to get hundreds of millions in fees	Jun. 07
J&J-backed Rapport Therapeutics shares debut nearly 6% higher	Jun. 07
J&J : la FDA approuve VELYS dans l'arthroplastie du genou	Jun. 07
AbbVie's tight grip on Humira market raises concerns about biosimilars	Jun. 07
J&J-backed Rapport Therapeutics raises $136 mln in US IPO	Jun. 06
Borsa di Italia: Verso l'infinito e oltre	Jun. 06
Bolsa de Madrid: Hasta el infinito y más allá	Jun. 06
J&J : sollicite la FDA une indiation élargie du Prezcobix	Jun. 05
J&J : essai concluant pour Carvykti dans le myélome multiple	Jun. 04
J&J : essai prometteur pour Tecvayli dans le myélome multiple	Jun. 04
Johnson & Johnson Ordered to Pay $260 Million In Talc Powder Case	Jun. 04
Borsa di Italia: Mai contenti!	Jun. 04
J&J must pay $260 million in latest talc trial, Oregon jury says	Jun. 03
Legend Biotech Says Phase 2 Trial of Carvykti to Treat Multiple Myeloma Showed 'Deep, Durable' Responses	Jun. 03
Johnson & Johnson Announces Results from a Subgroup Analysis of the Phase 3 CARTITUDE-4 Study	Jun. 03
Johnson & Johnson Announces Data from the Phase 3 PERSEUS Study	Jun. 03
Johnson & Johnson Announces New Data from the Phase 2 PALOMA-2 Study Evaluating Subcutaneous (SC) Amivantamab Combined with Lazertinib as First-Line Treatment in Patients with Advanced Non-Small Cell Lung Cancer	Jun. 03
Johnson & Johnson Announces Longer-Term Data from the Pivotal Phase 1/2 Majestec-1 Study of TECVAYLI	Jun. 03
J&J-backed Rapport Therapeutics seeks about $637 mln valuation in US IPO	Jun. 03
J&J-backed Rapport Therapeutics seeks to raise $144 mln in US IPO	Jun. 03

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Joseph Wolk, CFO of J&J: End of patent for its flagship drug

January 23, 2024 at 12:30 pm EST